Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03830125 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BBT-877 in Healthy Subjects
A Phase 1 study, sponsored by Bridge Biotherapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 88
- Enrollment target
NCT03830125: Completed Phase 1 study, sponsored by Bridge Biotherapeutics.
NCT03830125 is a Phase 1 study that has completed, run by Bridge Biotherapeutics. The registered enrollment target is 88 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (47% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03830125, a Phase 1 study, has completed, sponsored by Bridge Biotherapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 88 participants
- Enrollment target
Study Summary
This clinical trial is the first-in-human study of BBT-877. The purpose of this phase 1 study is to assess the safety and tolerability of single and multiple ascending oral doses of BBT-877 in healthy adult subjects.
Primary Outcome
To assess the safety and tolerability of single and multiple ascending oral doses of BBT-877 in healthy adult subjects.
Interventions
- DRUG Placebo group
- DRUG BBT-877, Single dose
- DRUG BBT-877, Multiple doses
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2019-02-13 |
| Est. Completion | 2019-11-24 |
| Phase | Phase 1 |
What the finished NCT03830125 record still lists
NCT03830125 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 88 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (47% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo group is the first listed.
NCT03830125 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03830125 about?
NCT03830125 is a clinical study titled "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BBT-877 in Healthy Subjects". This clinical trial is the first-in-human study of BBT-877. The purpose of this phase 1 study is to assess the safety and tolerability of single and multiple ascending oral doses of BBT-877 in healthy adult subjects.
What is the current status of trial NCT03830125?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 88 participants. The study started on 2019-02-13. Estimated completion is 2019-11-24.
What interventions are being tested in trial NCT03830125?
The interventions under investigation include: Placebo group (DRUG), BBT-877, Single dose (DRUG), BBT-877, Multiple doses (DRUG).
Who is sponsoring clinical trial NCT03830125?
This trial is sponsored by Bridge Biotherapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03830125's enrollment target sits among peer trials
88 650th of 2000 higher than 1,350 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03843463 · 88 participants · Phase 2
Escitalopram and Language Intervention for Subacute Aphasia
- NCT04066348 · 88 participants · Phase 2
TNF-α Treatment of Blast-Induced Tinnitus
- NCT04331704 · 88 participants · Phase 4
ANCHORS Alcohol & Sexual Health Study: UH3 Project
- NCT04536103 · 88 participants
Multi-Vendor Multi-Site Novel Accelerated MRI Relaxometry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI